AbbVie

News

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren

News

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.

News

AbbVie files Vraylar as add-on therapy for depression in US

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the dr

News

Aldeyra builds case for troubled dry eye drug reproxalap

Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h

News

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status.

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

AbbVie files Vraylar as add-on therapy for depression in US

Aldeyra builds case for troubled dry eye drug reproxalap

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

Leo puts target on Dupixent in US as FDA clears tralokinumab

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AbbVie

Editor's Picks